15 years of revenue, profit, cash flow and balance-sheet history through FY2025, from SEC filings — with a computed, factual read of the trend. Updated Overview →
| FY | Revenue | Net income | Gross M | Op M | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|
| 2025 | $228M | $31M | 74.5% | 16.3% | $42M | $23M | $30M |
| 2024 | $230M | $30M | 72.1% | 13.4% | $39M | $68M | $69M |
| 2023 | $236M | $22M | 73.4% | 13.9% | $27M | $102M | $85M |
| 2022 | $228M | $2000 | 75.8% | 10.4% | -$16M | $102M | $76M |
| 2021 | $253M | $29M | 74.8% | 0.5% | $21M | $102M | $63M |
| 2020 | $225M | -$60M | 82.5% | -13.5% | $727000 | $84M | $85M |
| 2019 | $272M | -$76M | 86.5% | -14.3% | $22M | $95M | $60M |
| 2018 | $251M | -$114M | 86.2% | -37.7% | -$25M | $152M | $108M |
| 2017 | $28M | -$292M | 79.9% | -1056.1% | -$173M | $48M | $82M |
| 2016 | — | -$276M | — | — | -$146M | — | $194M |
| 2015 | — | -$239M | — | — | — | — | $32M |
| 2014 | — | -$142M | — | — | — | — | $39M |
| 2014 | — | -$234M | — | — | — | — | $28M |
| 2014 | — | -$198M | — | — | — | — | $55M |
| 2014 | — | -$159M | — | — | — | — | $163M |
| Quarter | Revenue | Net income | Gross M | Op M | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|
| Mar '26 | $45M | -$4M | 76.7% | -8.5% | $15M | $11M | $36M |
| Dec '25 | $75M | $13M | 69.3% | 22.7% | $14M | $23M | $30M |
| Sep '25 | $54M | $9M | 77.7% | 17.6% | $10M | $34M | $54M |
| Jun '25 | $52M | $6M | 76.5% | 12.7% | $14M | $45M | $55M |
| Mar '25 | $46M | $3M | 77.1% | 8.7% | $4M | $57M | $63M |
| Dec '24 | $59M | $19M | 76.4% | 22.6% | $16M | $68M | $69M |
| Sep '24 | $81M | $20M | 63.9% | 27.4% | $11M | $79M | $67M |
| Jun '24 | $47M | -$5M | 77.4% | -4.6% | $1M | $91M | $67M |
| Mar '24 | $44M | -$5M | 75.5% | -5.3% | $11M | $102M | $77M |
| Dec '23 | $72M | $12M | 66.3% | 20.5% | $10M | $102M | $85M |
| Sep '23 | $56M | $6M | 76.3% | 15.3% | $11M | $102M | $82M |
| Jun '23 | $55M | $2M | 78.3% | 9.0% | — | $102M | $60M |
| Mar '23 | $53M | $1M | 75.0% | 8.3% | — | $102M | $61M |
| Dec '22 | $66M | -$6M | 74.4% | 15.3% | $8M | $102M | $76M |
| Sep '22 | $57M | -$360000 | 78.1% | 4.2% | $17M | $102M | $78M |
| Jun '22 | $60M | $9M | 74.9% | 20.3% | — | $102M | $53M |
| Mar '22 | $46M | -$3M | 76.3% | -1.6% | — | $102M | $64M |
| Dec '21 | $55M | $4M | 78.5% | 12.3% | -$5M | $102M | $63M |
| Sep '21 | $46M | -$45M | 77.8% | -19.4% | — | $102M | $64M |
| Jun '21 | $53M | -$5M | 77.6% | -31.2% | — | $69M | $90M |
How the market has priced PBYI against its own fundamentals since 2023-03 — each month-end's share price set against the most recent annual filing, so the multiple moves as price runs ahead of (or behind) earnings. Split-adjusted.
Over the past 5 years, PUMA BIOTECHNOLOGY, INC.'s revenue has grown 0.3% per year. These are computed facts, not advice.
As of FY2025, PUMA BIOTECHNOLOGY, INC. reported $23M of total debt against $30M of cash; operating income covered interest expense 5.6×.
In FY2025, gross margin was 74.5%, operating margin 16.3%, and net margin 13.6%.
As of Jun '26, PUMA BIOTECHNOLOGY, INC. traded at a price-to-earnings ratio of about 12.6× (market cap ÷ latest annual net income). The valuation charts above show how its P/E, P/S have moved with the share price. These are computed facts, not advice.
All figures are extracted from the company’s SEC EDGAR/XBRL filings — 10-K annual reports and 10-Q quarterly reports (use the Annual / Quarterly toggle). Quarterly figures are derived from the as-filed statements (year-to-date amounts are differenced into discrete quarters). Growth rates and ratios are computed by tradmap; nothing here is investment advice.
Source: SEC EDGAR / XBRL (10-K + 10-Q filings) · prices EOD (Databento), corporate-action-adjusted · growth rates, valuation multiples & ratios computed by tradmap. Valuation uses each month-end price against the latest annual filing. Informational only — not investment advice.